Dr. Murat Kalayoglu, President and CEO at Cartesian Therapeutics, provides an update since his last visit on their cell and gene therapies, as well as fundraising successes.
Listen now on Apple https://apple.co/2SuVe2M, Google https://bit.ly/35Uq6wV, Spotify https://spoti.fi/3w3d7nd, or TuneIn https://bit.ly/2U9zYjL
Dr. Murat Kalayoglu is President and CEO at Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology. The company, founded in 2016, with three assets in clinical trials, is the leader in RNA cell therapy with products in development for autoimmune, oncologic and respiratory disorders. Cartesian’s investigational therapies are manufactured at a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD. Prior to Cartesian, Dr. Kalayoglu was co-founder and CEO of Topokine, which he led from concept to late-stage clinical trials, followed by a successful sale to Allergan. Dr. Kalayoglu was also co-founder and COO of HealthHonors Corporation, which he led from concept to commercialization, followed by a successful sale to Healthways. Dr. Kalayoglu is a board-certified ophthalmologist who completed his residency and research Fellowship at Harvard, MD/PhD in immunology at the University of Wisconsin-Madison, and MBA from the MIT Sloan School of Management.